DCVC Bio
VC Fund
San Francisco, United States
DCVC Bio is a venture capital fund that invests in early-stage life science companies driven by deep-tech approaches. Advances in genetic sequencing, artificial intelligence, and automation are converging to transform existing life sciences technologies and speed the development of new ones. The firm is looking for companies affecting deeptechnological change in synthetic biology, medicine, and agriculture.
- Total investments:
- 72
- Last investment:
- Lead investor:
- 60%
- Fund size:
- $350M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries DCVC Bio invests in
Stages DCVC Bio invests in
Countries DCVC Bio invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2M–$31M
- Series A
- $13M–$67M
- Series B
- $27M–$135M
Investment Focus
Industry
- Biotechnology 27 (38%)
- Therapeutics 12 (17%)
- Medical 11 (15%)
- Health Care 8 (11%)
- Pharmaceutical 8 (11%)
Stage
- Series A 29 (40%)
- Seed 11 (15%)
- Series B 11 (15%)
- Series C 4 (6%)
- Series D 1 (1%)
Country
- United States 32 (44%)
- United Kingdom 2 (3%)
- Canada 1 (1%)
- Denmark 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andy May
Entrepreneur In Residence
|
Entrepreneur In Residence | Total investments: 1 | Find email | |
Anna Fokina
Investment Director
|
Investment Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing. | $43M / Series A / May 04, 2026 | ||
| Sidewinder Therapeutics develops bispecific antibody-drug conjugates (ADCs) aimed at treating solid tumors. Their mission is to create life-saving therapies through precision therapeutics. | $137M / Series B / Apr 08, 2026 | ||
| AgZen develops pesticide sprays stick to plants which reduces pollution and helps farmers save. | $10M / Series B / Mar 13, 2026 | ||
| NILO Therapeutics is a biotechnology and therapeutics company. | $101M / Series A / Oct 08, 2025 | ||
| Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. | $32M / Series A / Sep 09, 2025 | ||
| Estes Energy is a California-based startup developing advanced, U.S.-made, chemistry-agnostic battery packs for mobility and industry—supporting both NMC (for high energy density) and LFP (for cost-sensitive applications)—and targeting commercial vehicles, defense, marine, rail, and off-highway markets. | $11M / Seed / Jul 23, 2025 | ||
| Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges, focused on the discovery and development of a novel class of “protein-like polymers” to treat significant unmet medical needs in chronic inflammatory and neurodegenerative diseases. | $30M / Series A / Apr 23, 2025 | ||
| Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells. | $41M / Series A / Apr 09, 2025 | ||
| AgZen develops pesticide sprays stick to plants which reduces pollution and helps farmers save. | $10M / Series A / Mar 06, 2025 | ||
| Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines. | $93.5M / Series A / Feb 13, 2025 | ||
| See all 72 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does DCVC Bio invest in?
DCVC Bio invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series A and Seed stage. Most of the 72 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is DCVC Bio's check size?
DCVC Bio typically joins rounds of $2M–$31M at Seed, $13M–$67M at Series A and $27M–$135M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DCVC Bio participates in.
How do I contact DCVC Bio?
Public channels for DCVC Bio include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DCVC Bio?
The team at DCVC Bio includes Andy May (Entrepreneur In Residence) and Anna Fokina (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
